In this work the importance of the potentiation and recovery of the balance with a physiotherapeutic intervention that begins in the early preoperative phase is compared with the conventional postoperative rehabilitation. The objective is to evaluate the influence of a muscle enhancement protocol in which a specific work of balance is included, with the physical benefits that this entails for the evolution of the patient. It also seeks to verify if the teaching and recommendation of exercises at home as preparation and conditioning for the intervention of ATR is effective, and to what extent, compared to a guided training in the hospital.

Start Date12 Apr 2017

Sponsor / Collaborator

University of Valencia

[+1]

100 Clinical Results associated with Hospital Universitari i Politècnic La Fe

0 Patents (Medical) associated with Hospital Universitari i Politècnic La Fe

1,977

Literatures (Medical) associated with Hospital Universitari i Politècnic La Fe

31 Dec 2024·Scandinavian Cardiovascular Journal

Lower heart rate in patients with acute heart failure: the role of left ventricular ejection fraction

Article

Author: Villar, Sandra ; Palau, Patricia ; Núñez, Julio ; Núñez, Eduardo ; Lorenzo, Miguel ; Santas, Enrique ; Sanchis, Juan ; Miñana, Gema ; Donoso, Victor ; Bayés-Genis, Antoni ; Núñez, Gonzalo ; de la Espriella, Rafael

BACKGROUNDThe clinical impact of heart rate (HR) in heart failure with preserved ejection fraction (HFpEF) is a matter of debate. Among those with HFpEF, chronotropic incompetence (CI) has emerged as a pathophysiological mechanism linked to the severity of the disease. In this study, we sought to evaluate whether admission heart rate in acute heart failure differs along left ventricular ejection fraction (LVEF).METHODSWe included retrospectively 3,712 consecutive patients admitted for acute heart failure (AHF) in the Cardiology department of a third level center. HR values were assessed at presentation. LVEF was assessed by transthoracic echocardiogram during the index admission and stratified into four categories: reduced ejection fraction (__-mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML"-__≤40%), mildly reduced ejection fraction (41-49%), preserved ejection fraction (50-64%) and supranormal ejection fraction (__-mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML"-__≥65%). The association between HR and LVEF was assessed by multivariate linear and multinomial regression analyses.RESULTSThe mean age of the sample was 73,9 ± 11.3 years, 1,734 (47,4%) were women, and 1,214 (33,2%), 570 (15,6%), 1,229 (33,6%) and 648 (17,7%) patients showed LVEF __-mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML"-__≤40%, 41-49%, 50-64%, and ≥65% respectively. The median HR at admission was 95 (IQR 78-120) beats per minute and 1,653 were on atrial fibrillation (45.2%). There was an inverse relationship between HR at admission and LVEF. Lower HR was significantly associated with a higher LVEF in the whole sample (p < 0,001). This inverse relationship was found in sinus rhythm but not in patients with atrial fibrillation.CONCLUSIONHR at admission for AHF is a predictor of LVEF but only in patients with sinus rhythm.

01 Dec 2024·Cellular and Molecular Life Sciences

HMGA1 regulates trabectedin sensitivity in advanced soft-tissue sarcoma (STS): A Spanish Group for Research on Sarcomas (GEIS) study

Article

Author: Mondaza-Hernandez, Jose L ; Ramos, Rafael ; Martinez-Trufero, Javier ; Martin-Ruiz, Marta ; Romero-Gonzalez, Pablo ; Bagué, Silvia ; Lopez-Alvarez, Maria ; Marcilla, David ; Izquierdo, Francisco ; Moura, David S ; Cordero-Varela, Juan A ; Carrillo-Garcia, Jaime ; Salgado, Maria Angeles Vaz ; Martin-Davila, Francisco ; Renshaw-Calderon, Marta ; Romagosa, Cleofe ; Valverde, Claudia ; Martin-Broto, Javier ; Hindi, Nadia ; Castilla-Ramirez, Carolina ; Agra-Pujol, Carolina ; Sanchez-Bustos, Paloma ; Lavernia, Javier ; Peña-Chilet, Maria ; Garcia-Foncillas, Jesus ; Hernandez-Leon, Carmen Nieves ; Ortega-Medina, Luis ; Alvarez-Alegret, Ramiro ; Dopazo, Joaquin ; Gutierrez, Antonio ; Alvarez, Rosa ; Mayodormo-Aranda, Empar

AbstractHMGA1 is a structural epigenetic chromatin factor that has been associated with tumor progression and drug resistance. Here, we reported the prognostic/predictive value of HMGA1 for trabectedin in advanced soft-tissue sarcoma (STS) and the effect of inhibiting HMGA1 or the mTOR downstream pathway in trabectedin activity. The prognostic/predictive value of HMGA1 expression was assessed in a cohort of 301 STS patients at mRNA (n = 133) and protein level (n = 272), by HTG EdgeSeq transcriptomics and immunohistochemistry, respectively. The effect of HMGA1 silencing on trabectedin activity and gene expression profiling was measured in leiomyosarcoma cells. The effect of combining mTOR inhibitors with trabectedin was assessed on cell viability in vitro studies, whereas in vivo studies tested the activity of this combination. HMGA1 mRNA and protein expression were significantly associated with worse progression-free survival of trabectedin and worse overall survival in STS. HMGA1 silencing sensitized leiomyosarcoma cells for trabectedin treatment, reducing the spheroid area and increasing cell death. The downregulation of HGMA1 significantly decreased the enrichment of some specific gene sets, including the PI3K/AKT/mTOR pathway. The inhibition of mTOR, sensitized leiomyosarcoma cultures for trabectedin treatment, increasing cell death. In in vivo studies, the combination of rapamycin with trabectedin downregulated HMGA1 expression and stabilized tumor growth of 3-methylcholantrene-induced sarcoma-like models. HMGA1 is an adverse prognostic factor for trabectedin treatment in advanced STS. HMGA1 silencing increases trabectedin efficacy, in part by modulating the mTOR signaling pathway. Trabectedin plus mTOR inhibitors are active in preclinical models of sarcoma, downregulating HMGA1 expression levels and stabilizing tumor growth.

01 Nov 2024·Respiratory Investigation

Cough severity visual analog scale scores and quality of life in patients with refractory or unexplained chronic cough

Article

Author: González-Barcala, Francisco Javier ; Quirce, Santiago ; Domingo, Christian ; Cea-Calvo, Luis ; Sánchez-Jareño, Marta ; Puente-Maestu, Luis ; Crespo-Lessman, Astrid ; De Diego, Alfredo ; López-Cotarelo, Pilar ; Pérez de Llano, Luis ; Dávila, Ignacio ; Arismendi, Ebymar

BACKGROUNDRefractory chronic cough (RCC) and unexplained chronic cough (UCC) adversely affect patients' quality of life (QoL). This multicenter, non-interventional study evaluates the relationship between cough severity and QoL and other patient-reported outcomes (PROs) in Spanish outpatients.METHODSRCC/UCC patients self-administered a printed survey comprising the cough-severity visual analog scale (VAS), adapted Cough Severity Diary (CSD), and Leicester Cough Questionnaire (LCQ), plus purpose-designed items regarding the physical and everyday-life impact of cough. Patients were stratified into VAS score tertiles. The impact of cough on QoL and other PROs in each tertile, and relationships between LCQ scores and the tertiles, were assessed.RESULTSThe VAS was completed by 189 patients, and VAS score tertiles were identified as 0-50, 60-70, and 80-100 mm. The only between-tertile difference in demographic or cough characteristics was cough duration. VAS score tertiles were linearly associated with mean LCQ domain and total scores, as well as the proportion of patients with the highest scores on all adapted CSD items, and almost all physical and everyday-life impact items. In multiple linear-regression models, an increase of one tertile in the VAS score was associated with a decrease of 2.23 points in the LCQ total score, indicating poorer cough-related QoL.CONCLUSIONAs self-assessed in patients with RCC/UCC, cough-severity VAS scores were strongly associated with the impact of cough on QoL and everyday life. Patients with VAS scores of 60-100 mm reported the greatest impact and thus may benefit the most from targeted cough therapies.

100 Deals associated with Hospital Universitari i Politècnic La Fe

100 Translational Medicine associated with Hospital Universitari i Politècnic La Fe

Corporation Tree

Boost your research with our corporation tree data.

view full example data

Pipeline

Pipeline Snapshot as of 23 Nov 2024

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Phase 1 Clinical

Current Projects

Drug(Targets)	Indications	Global Highest Phase

VOB-560 ( Bcl-2 )	Acute Myeloid Leukemia More	Phase 1

Deal

Boost your decision using our deal data.

view full example data

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Profit

Explore the financial positions of over 360K organizations with Synapse.

view full example data

Grant & Funding(NIH)

Access more than 2 million grant and funding information to elevate your research journey.

view full example data

Investment

Gain insights on the latest company investments from start-ups to established corporations.

view full example data

Financing

Unearth financing trends to validate and advance investment opportunities.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis